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The  H7N9  inﬂuenza  virus  caused  signiﬁcant  mortality  and  morbidity  in  humans  during  an  outbreak  in
China  in  2013.  A  recombinant  H7N9  inﬂuenza  seed  with  hemagglutinin  (HA)  and  neuraminidase  (NA)
gene  segments  from  A/Zhejiang/DTID-ZJU01/2013(H7N9)  and  six  internal  protein  gene segments  from
A/Puerto  Rico/8/34(H1N1;  PR8)  were  generated  using  reverse  genetics.  We  sought  to determine  the
immunogenic,  protective  properties,  and  mechanisms  of  a split  avian  inﬂuenza  A/H7N9  vaccine  mixed
with  MF59  adjuvant  in comparison  to vaccines  that  included  other  adjuvant.  BALB/c  mice  were  vaccinated
with  two doses  of  different  amounts  and combinations  of  this  novel  A/ZJU01/PR8/2013  split  vaccine  with
adjuvant.  Mice  were  subsequently  challenged  with  A/Zhejiang/DTID-ZJU01/2013(H7N9)  by intranasal
inoculation.  We veriﬁed  that MF59  enhanced  the  HI, MN,  and  IgG antibody  titers  to  inﬂuenza  antigens.mmunity
ytokines
Compared  with  alum,  MF59  could  more  potentially  induce  humoral  immune  responses  and  Th2  cytokine
production  after  virus  infection,  while  both  MF59  and  alum  can  slightly  increase  NK  cell activity.  This split
H7N9  inﬂuenza  vaccine  with  MF59  adjuvant  could  effectively  induce  antibody  production  and  protect
mice  from  H7N9  virus  challenge.  We  have  selected  this  vaccine  for manufacture  and  future  clinical  studies
to protect  humans  from  H7N9  virus  infection.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
The threat of a novel inﬂuenza H7N9 virus, A/Shanghai/1/2013
H7N9), and related isolates were highlighted by outbreaks in
hina in March 2013 [1]. Subsequently, a second wave of infections
ccurred in the winter of 2013–2014 [2]. A total of 571 cases that
aused 212 deaths (37.1%) had been reported to the World Health
rganization by February 23, 2015 [3].
A more feasible approach to reducing the impact of a pan-emic would require the development of safe and effective vaccines
gainst H7N9 [4]. One recent advance in inﬂuenza vaccine produc-
ion is the utilization of plasmid-based reverse genetics systems [5],
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nfectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of
nfectious Diseases, The First Afﬁliated Hospital, School of Medicine, Zhejiang Uni-
ersity, Hangzhou 310003, China. Tel.: +86 13906514210; fax: +86 057187236459.
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E-mail address: ljli@zju.edu.cn (L. Li).
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ttp://dx.doi.org/10.1016/j.vaccine.2016.03.037
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
which can provide advantages in the development of seed strains,
such as decontaminate to remove pathogenic traits at the plasmid
stage [6]. Reverse genetics technology has been applied to con-
struct candidate viruses that harbor HA and NA glycoproteins of
A/Zhejiang/DTID-ZJU01/2013(H7N9), while all other internal genes
were derived from A/Puerto Rico/8/34(H1N1; PR8). Subunit vac-
cines, such as split or subvirion vaccines, are thought to be safer
alternatives. HA is the mainstay of conventional inﬂuenza vaccine
approaches [7], efforts to develop vaccines against H7-containing
subtypes have been hampered because these HAs are poor vaccine
antigens [8–10], although antibody responses could be improved
substantially with adjuvants. The oil-in-water adjuvant MF59 has
been reported to improve the antibody response, permit dose spar-
ing, enhance efﬁcacy, and lower the antigen dose required to induce
protection. It also has an acceptable safety proﬁle when paired with
inactivated inﬂuenza vaccines [11,12]. Clinical trial also veriﬁed the
MF59 adjuvant even boost the 3.75 g split H7N9 to achieve a HI
titer of 40 or greater [13]. Alum is a conventional adjuvant that has
been used for over 80 years, and is the only adjuvant that is cur-
rently widely licensed for human use [14]. To determine whether
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Experimental grouping: H7N9 groups, immunized with split H7N9 vaccine alone;
H7N9+MF59 groups, immunized with MF59 adjuvant H7N9; Yuganning groups,
immunized with various amounts of Yuganning; H7N9 + Al(OH)3 groups, immu-
nized with split H7N9 vaccine plus Al(OH)3 adjuvant; PBS group, administered PBS
alone; w/o, without.
Components Group No. HA content
(g/ml/animal)
Adjuvant
H7N9
1 3 g/mouse w/o
2  0.6 g/mouse w/o
3  0.12 g/mouse w/o
4 0.024 g/mouse w/o
H7N9 + MF59
5 3 g/mouse MF  59 0.05 ml/mouse
6  0.6 g/mouse MF  59 0.01 ml/mouse
7  0.12 g/mouse MF  59 0.002 ml/mouse
8 0.024 g/mouse MF  59 0.0004 ml/mouse
MF59
9  w/o MF  59 0.05 ml/mouse
10  w/o MF  59 0.01 ml/mouse
11  w/o MF  59 0.002 ml/mouse
12 w/o MF  59 0.0004 ml/mouse
H7N9 + MF59
13 0.6 g/mouse MF  59 0.05 ml/mouse
14  0.12 g/mouse MF  59 0.05 ml/mouse
15  0.024 g/mouse MF  59 0.05 ml/mouse
Yuganning
16  3 g/mouse w/o
17  0.6 g/mouse w/o
18  0.12 g/mouse w/o
19 0.024 g/mouse w/o
H7N9 + Al(OH)3
20 3 g/mouse Al(OH)3 0.08 mg/mouse
21  0.6 g/mouse Al(OH)3 0.016 mg/mouse
22 0.12 g/mouse Al(OH)3 0.0032 mg/mouseH. Ou et al. / Vaccin
F59 or alum was a better adjuvant for this H7N9 inﬂuenza split
accine, we compared the adjuvanticity of MF59 and other adju-
anted split vaccines.
Several H7N9 seed strains, which were mostly generated
sing HA and NA sequences of the A/Shanghai/2/2013 and
/Anhui/1/2013 strains, form the basis of H7N9 candidate vac-
ines [15]. Importantly, this split vaccine is the ﬁrst to use the
/Zhejiang/1/2013 strain. Herein, we carried out these preclinical
xperiments in a relatively comprehensive and systematic manner
o evaluate the immunogenicity and mechanisms of this split avian
nﬂuenza A/H7N9 vaccine mixed with MF59 adjuvant in mice.
. Materials and methods
Male BALB/c mice that were 6–7 weeks old were purchased
rom Joint Ventures SIPPER-BK Experimental Animal Co. (Shanghai,
hina). All animal studies were performed in accord with the
uide for the Care and Use of Laboratory Animals of Zhejiang
rovince and were approved by the local Ethics Committee. Zhe-
iang Tianyuan Bio-Pharmaceutical Co., Ltd. (which was afﬁliated
ith Novartis Vaccine Inc.) provided the MF59TM adjuvant (MF59
s a trade mark of Novartis AG and Afﬁliate Companies) and the
uganning seasonal ﬂu vaccine, which contains 15 g HA of each of
he following substances: A/California/7/2009(H1N1) pdm09-like
irus, A/Texas/50/2012(H3N2) virus, and B/Massachusetts/2/2012-
ike virus. Madin-Darby canine kidney cell line (MDCK) and Yac-1
ere obtained from ATCC (Rockville, MD,  USA).
.1. Viruses and vaccines
The A/Zhejiang/DTID-ZJU01/2013(H7N9) virus was  isolated
rom a patient in Zhejiang Province, China in 2013, by transfect-
ng 8 individual pHW2000 plasmids into Vero cells [5], we  created
 A/ZJU01/PR8/2013 vaccine seed strain which harbored HA and NA
enes from the aforementioned virus and six internal genes from
he PR8 virus, then the seed virus was grown to a high titer in eggs
nd the virions were puriﬁed by centrifugation, inactivated with
ormalin, and ﬁltered to remove bacteria. The H7N9 split vaccines
ere produced under Good Manufacturing Practices.
.2. Animal immunization
Groups (n = 12) of male 6 to 7-week-old BALB/c mice that
eighed 22 ± 2 g were immunized twice with 100 l with 100 l
f either split vaccine alone, MF59 alone, MF59-adjuvant vaccine,
lum-adjuvant vaccine, seasonal ﬂu vaccine (Yuganning), or PBS
y intramuscular injection in the hind legs (half dose per injection
ite) at a 2-week interval (Table 1). All animals were bled via the
ail vein on the day before each immunization and virus incubation
nd again 1 week after virus incubation. Lack of pre-existing immu-
ity against inﬂuenza virus was ascertained in all mice, which was
eﬁned as hemagglutinin inhibition (HI) activity ≤10.
.3. Virus inoculation
At 2 weeks after the second immunization, mice in each group
n = 6) were inoculated intranasally with 50 l 106 TCID50 wild type
7N9 virus A/Zhejiang/DTID-ZJU01/2013(H7N9) diluted in PBS.
he TCID50 assay was performed according to the recommended
rotocol of the World Health Organization [16,17]. Mice were
bserved for illness, weight loss, and death for 7 days after infec-
ion. Then, mice were sacriﬁced and lungs were removed—parts of
he lungs were ﬁxed in 10% buffered formalin or were harvested
nd used to determine the virus titers using TCID50 assay.23  0.024 g/mouse Al(OH)3 0.00064 mg/mouse
PBS 24 0.1 ml/mouse
2.4. HI test
All serum samples were treated with receptor destroying
enzyme [18]. Prior to HI tests, a two-fold serial dilution series of
serum was mixed 1:1 with four hemagglutinating units of virus
(wild type H7N9 virus A/Zhejiang/DTID-ZJU01/2013(H7N9)) and
incubated at 37 ◦C for 1 h. Subsequently, 50 l 1% chicken eryth-
rocytes were added, mixed, and incubated for 1 h at 4 ◦C; all
agglutination patterns were read within 10 min.
2.5. Micro-neutralization (MN) assay
MDCK cells were seeded at 2 × 104 cells/well in 96-well plates
and cultured to 80–90% conﬂuency at 37 ◦C. Heat-inactived serum
samples were diluted 1:10 with DMEM,  then were serially diluted
two-fold and mixed with 50 l of 100 TCID50 A/Zhejiang/DTID-
ZJU01/2013(H7N9) virus for 1 h at 37 ◦C. Cells were incubated in the
presence of TPCK-treated trypsin at 37 ◦C for 72 h post-infection.
Cell supernatants were harvested and transferred to V-bottom
96-wells plates. The presence of virus was  detected using a hemag-
glutination assay.
2.6. Immunoglobulin G enzyme-linked immunosorbent assay
(IgG-ELISA)
96-wells of polyvinyl chloride microtiter plates (Falcon, USA)
were coated overnight at 4 ◦C with 10 g/well HA antigen in PBS
coating solution (KPL, USA). At room temperature, wells were
coated with 1% bovine serum albumin (Sigma–Aldrich, USA) and
incubated for 2 h after three washes. Next, wells were washed
and 2-fold serial dilutions of serum were inoculated in 100 l
volumes for 1 h. Plates were again washed, and 100 l peroxidase-
labeled rabbit anti-mouse immunoglobulin G (Zymed, USA) was
added to each well and incubated for 2 h. After another wash,
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00 l/well substrate TMB  (Sigma) was added and then the reac-
ion was stopped. Absorbance was measured at 450 nm.  ELISA
iters were expressed as reciprocal dilutions and yielded an OD
hat was higher than the average OD of the blanks plus 3 times
he SD.
.7. Splenocyte proliferation assays
Spleens were aseptically removed from mice 2 weeks after the
nal immunization and were gently dissociated through a stainless
teel sieve into RPMI medium supplemented with 5% FBS. Spleno-
ytes were collected by pelleting at 1200 rpm in a Beckman GPKR
entrifuge. Erythrocytes were lysed for 1 min  in 155 mM NH4Cl,
7 mM Tris–HCl (pH 7.2).
50 l triplicates of splenocyte suspensions (5 × 106 cells/ml) in
omplete RPMI-1640 medium with 5% FBS in 96-well plates were
timulated with 10 g/50 l HA for 72 h. After inoculation, 100 l
reshly prepared reconstituted Cell Titer-Glo reagent (Promega)
as added to all wells, which were mixed for 2 min  and then incu-
ated for 10 min. Luminescence intensity was measured using the
loMax®-Multi Detection System (Promega).
.8. Determination of NK cell activity and cytotoxic T lymphocyte
CTL) activity
The NK activities of splencytes were measured: 96-well plates
ontaining various amounts of splenocytes and 104 Yac-1 cells per
ell in 200 l RPMI-1640 supplemented with 5% FBS were incu-
ated for 72 h. Then the percentage of speciﬁc lysis was  determined
sing a Cytotox96 non-radioactive cytotoxicity assay (Promega),
nd samples (50 l) from each well were transferred to fresh 96-
ell ﬂat-bottom plates. Reconstituted substrate mixtures (50 l)
ere added to each well, which were incubated for 30 min  at room
emperature. Stop solution (50 l) was added before absorbance
f samples was measured at 490 nM on an automated plate
eader.
The CTL activity of splencytes was measured: target cells were
repared using 107 Yac-1 cells co-cultured with 10 g/ml HA. Then,
04 target cells and various amounts of effector splenocytes were
dded to each well of the 24-well plates then incubated for 4 h. The
ercentage of speciﬁc lysis was determined as described above for
K cell activity.
.9. Immunoassay–Luminex measurement
Splenocytes cultured at 5 × 106/well were seeded into 24-well
lates in 5% FBS RPMI-1640 medium. Cells were cultured either in
he presence or absence of 10 g/ml HA antigen, and then super-
atants were collected after a 72 h activation period.
Serum samples and supernatants from stimulated splenocytes
ere measured using multiplex bead assays (MCYTMAG-70K-
X32, Millipore; USA) incorporated into MILLIPLEX MAP panels that
e ran on a Luminex 200 instrument. Samples were ﬁrst diluted
s recommended, and bead–antibody complexes were vortexed. A
otal of 25 l assay buffer was added to either 25 l controls or sam-
les followed by the addition of 25 l bead–antibody complexes.
lates were incubated at 4 ◦C for 16 h with constant agitation. Plates
ere washed three times and then were incubated for 1 h with
5 l biotinylated detection antibody. Next, 25 l streptavidin–PE
as added to detection antibody for another 30 min. Finally, plates
ere washed, and beads were suspended in 100 l sheath ﬂuid.
or analysis, the 96-well plate was placed in a BioPlex reader and
ata were collected, analyzed, and quality controlled as previously
escribed by Lovestone [19].2016) 2362–2370
2.10. Virus titers and Immunohistochemistry of lung tissues
Viral lung titers were determined using 10-fold serial dilutions
of tissue extracts, and were tested for infectivity of MDCK cells in
96-well plates after 48 h incubation. Virus titers were estimated
based on the method of Reed and Muench.
Parafﬁn sections of lungs were dewaxed then subjected to Ag
retrieval by heat treatment, and endogenous peroxidase activity
was quenched with 0.3% H2O2 in methanol. Sections were blocked
for 1 h with 3% BSA in PBS and incubated sequentially overnight
at 4 ◦C with 1:400 dilution of polyclonal rabbit anti-H7N9 Ab; anti-
body binding was  detected using EnVision System reagents (DAKO,
Denmark). All slides were counterstained with hematoxylin.
2.11. Statistical analysis
Statistical analyses of data for HI titers, antibody titers, spleno-
cyte proliferation, NK cell activity, CTL activity, and virus titers were
performed using SPSS software (SPSS Inc., USA) using a two-way
ANOVA test with the Turkey post hoc assessment. Values represent
means ± SEM for indicated sample sizes. A threshold of p < 0.05 was
used to denote statistical signiﬁcance.
3. Results
3.1. Evaluation of antibody responses
Antibody responses in each of the 24 groups are shown in Fig. 1.
After the ﬁrst vaccination, the GMTs of HI titers in the groups immu-
nized with HA antigen (H7N9 vaccine with adjuvant or not and
Yuganning) all were within the range of 10–80, while all MN titers
were below the limit of detection (1:20).
After second boost, titers of HI, MN,  and IgG of groups immu-
nized with HA antigen increased substantially. We observed that
antibody titers declined in correlation with the reduction in the
amount of HA antigen. Reducing the HA antigen dose to 0.024 g
per mouse with or without adjuvant (MF59 or Alum) resulted in a
signiﬁcant reduction in antibody and MN titers to less than 40. By
comparing the same amount HA antigen with or without MF59, we
observed that MF59 adjuvant signiﬁcantly increased the immune
response (for the HI titer: p = 0.004, MN titer: p = 0.014, IgG titer
p = 0.128). There were also signiﬁcant differences between groups
of mice administered MF59 adjuvant vs. Alum adjuvant (HI titer
p = 0.016, MN  titer p = 0.033, IgG titer p = 0.017).
3.2. Cellular immune responses in each experimental group
The splenocyte proliferation levels (Fig. 2A) in mice immu-
nized with H7N9 antigen with or without adjuvant were higher
than those of animals vaccinated with PBS, Yuganning, or MF59
(p < 0.001). The difference between group vaccinated with H7N9
(group 1) and H7N9 + MF59 (group 5) was also signiﬁcant (p = 0.03),
while the difference between H7N9 + MF59 group (group 5) vs.
H7N9 + alum (group 20) was not (p = 0.2). MF59 and alum adjuvants
stimulate the innate immune response of splenocytes 2 weeks after
the second immunization. Using a standard 4 h NK cell assay against
YAC-1 targets (Fig. 2B), we revealed that the NK activity in the
adjuvant groups (MF59 and alum) was  slightly higher than that of
the PBS groups, while there was no signiﬁcant difference between
antigens administered with MF59 (group 5) or alum (group 20)
adjuvants (p = 0.4). We  found that the adjuvants alum and MF59
were poor inducers of CTL activities (Fig. 2C) and that there was no
signiﬁcant difference between antigens administered with either
MF59 or alum adjuvant (p = 0.5).
Fig. 3A shows systemic levels of cytokines in the serum. The
cytokines IL-4, IL-5, IL-6, IL-10 and IL-13 are mainly produced by
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Fig. 1. Measurements of antibody responses. (A) HI antibodies, (B) MN antibodies, and (C) IgG responses of all 24 groups measured 2 weeks after the ﬁrst immunization
and  2 weeks after the second boost. Each dot represents the geometric mean titer for groups of 6 mice. Mouse were intramuscular injected twice with various dosage of
following immune formulations: Groups 1, 2, 3 and 4 (H7N9), Groups 5, 6, 7 and 8 (H7N9 + MF59, dosage of MF59 decreased synchronize with dosage of H7N9 in these four
groups),  Groups 9, 10, 11 and 12 (MF59), Groups 13, 14, and 15 (H7N9 + MF59, dosage of MF59 maintained the highest dosage of 0.05 ml/mouse), Groups 16, 17, 18 and 19
(Yuganning); Groups 20, 21, 22 and 23 (H7N9 + alum); Groups 24 was PBS control group.
Fig. 2. In vivo assessments of HA-speciﬁc proliferation, NK cell activity, and CTL activity of splenocytes from group 1 (H7N9), group 5 (H7N9 + MF59), group 9 (MF59), group
16  (Yuganning), group 20 (H7N9 + alum), and group 24 (PBS) at 2 weeks after the second boost. (A) HA-speciﬁc splenocyte proliferation. A total of 10 g/50 l HA was applied
to  stimulate the 50 l volume, 5 × 106 cells/well splenocyte cultures in a 96-well plate for 72 h. Then, 100 l/well Cell Titer-Glo was added and the luminescence intensity was
measured. Stimulation index = luminescence intensity of HA antigen-stimulated cells/intensity of unstimulated cells. (B) Cytotox96 non-radioactive cytotoxicity assay to test
NK  cell activity. The X-axis indicates the ratio of splenocytes to Yac-1 cells (target cells 104/well). The Y-axis shows the cytotoxicity, which was measured using the following
formula: ([LDH in the mixture of target and effector cells − LDH spontaneously released from target cells and effector cells]/[total LDH of target cells − LDH spontaneously
r -Radi
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peleased from target cells]) × 100. (C) CTL activity was tested using a Cytotox96 Non
s  target cells. The percentage of speciﬁc lysis was  assumed to indicate NK cell activ
h2 cells. Immunization resulted in low, but detectable levels of IL-
, IL-6, and IL-10 in serum, whereas IL-4 was not detectable; levels
f all four of these cytokines increased after virus inoculation. By
ontrast, levels of IL-13 were relatively high after immunization,
ut decreased signiﬁcantly after virus inoculation. Levels of IL-6 and
L-13 expression signiﬁcantly increased in the H7N9 + MF59 group
fter the second immunization, while levels IL-4, IL-5, IL-6, IL-10,
L-13 were greatest in the H7N9 + MF59 group among all experi-
ental groups after virus inoculation (IL-4, IL-5, IL-6, and IL-10, all
 < 0.001; IL-13, p = 0.07). IL-17 is mainly produced by Th17 cells.oactive cytotoxicity assay. A total of 10 g/ml HA  pretreated Yac-1 cells were used
Detectable levels of IL-17 were not induced in the serum by a sin-
gle or second injection of any vaccine/adjuvant combination that
we tested. The group of mice that received MF59 + H7N9 exhibited
the highest levels of IL-17 after virus inoculation. The cytokines
IFN- and IL-2 are mainly produced by Th1 cells. IFN- and IL-2
levels varied throughout the period following immunization, and
the addition of MF59 adjuvants to the vaccine resulted in remark-
able changes IL-2 levels after virus inoculation (p = 0.018), but also
resulted in lower levels of IFN- during both the immunization
and virus inoculation periods (2 weeks, p = 0.95; 4 weeks, p = 0.65;
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 weeks, p = 0.83). The inclusion of alum only resulted in a slight
ncrease in the IL-2 response after virus inoculation, but levels of
FN- were reduced at all of these three various time points.
Most of the Th1 and Th2 cytokines increased when cocultured
ith H7N9 antigen (Fig. 3B). The addition of MF59 or alum adjuvant
o the H7N9 split vaccine induced strong Th2 cytokine responses,
ncluding IL-4, IL-5, IL-6, IL-10, and IL-13, as well as the Th17
ytokine IL-17. It has been observed that MF59 boosts levels of IL-4,
L-5, IL-10, and IL-17 more highly compared with alum (for each,
 < 0.05), while levels of IL-6 and Il-13 levels elicited by alum were
igher than those elicited by MF59 (for both, p < 0.05). The levels of
FN- secreted by splenocytes were inconsistent the levels detected
ig. 3. Systemic expression of Th1 (IFN- and, IL-12), Th2 (IL-4, IL-5, IL-6, IL-10, and IL-
H7N9  + MF59), group 9 (MF59), group 16 (Yuganning), group 20 (H7N9 + alum), and gro
xpression proﬁles were measured in serum from BALB/c mice 2 weeks after the ﬁrst imm
fter  virus inoculation (5 week). (B) A total of 5 × 106 splenocytes/well were cultured 2 w
A  antigen for 72 h. Culture supernatants were collected and tested.2016) 2362–2370
in the serum. IL-2 and IL-13 levels peaked in that group received
H7N9 + MF59 (both p < 0.05), whereas the cytokines IL-12 and IL-7
were not detectable in any of the groups.
3.3. Protective effects of each of the immune formulations
For most of groups, all antibody titers were signiﬁcantly
increased after virus inoculation (Fig. 4), as the antibody response
increased progressively with MF59 or Alum adjuvant, although the
MF59 adjuvant showed a slight advantage in stimulating humoral
responses. Groups 6, 7, 8 and 13 14, and 15 were compared sepa-
rately to evaluate the effects of different amounts of MF59 adjuvant
13), Th-17 (IL-17), and other cytokines (IL-2 and IL-7) in group 1 (H7N9), group 5
up 24 (PBS) mice, as measured using a multiplex Luminex LiquiChip. (A) Cytokine
unization (2 weeks), 2 weeks after the second immunization (4 week), and 1 week
eeks after the second immunization either in the presence or absence of 10 g/ml
H. Ou et al. / Vaccine 34 (2016) 2362–2370 2367
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group 6 vs. group 13: HI titer, p = 0.783; MN titer, p = 0.9; IgG titer,
 = 0.8; group 7 vs. group 14: HI titer, p = 0.9; MN titer, p = 0.5; IgG
iter, p = 0.04; group 8 vs. group 15: HI titer, p = 0.045; MN titer,
 = 0.036; IgG titer, p < 0.001), while for relatively large doses of HA
ntigen there was little impact of a ﬁve-fold increase or decrease of
F59 adjuvant concentration on the antibody response. The com-
arison of Group 4 vs. Group 15 showed that even 0.05 ml  MF59
ould enhance the antibody response to the smallest amount HA
ntigen tested, which was 0.024 g (HI titer, p = 0.016; MN titer,
 < 0.001; IgG titer, p < 0.001).
We  observed lethargy, rough hair and loss of appetite in the
mmunized mice after wide type H7N9 challenge but no deaths.
here were varying degrees of weight loss in all 24 experimen-
al groups (Fig. 5A). In a comparison of mice vaccinated with the
on-adjuvanted H7N9 vaccine, both MF59 and alum were effec-
ive in delaying weight loss. Weight loss in the Yuganning group
uggested that any cross-protection effect was negligible. Fig. 5B
hows an analysis of whether MF59 or alum could signiﬁcantly
educe viral titers compared with groups treated with H7N9 split
accine alone (p < 0.001), and indicates that H7N9 antigen was  more
ffective when paired MF59 adjuvant (p = 0.11).
The extent and characteristics of the lesions varied among
hese groups 1 week after virus inoculation (Fig. 6). The H7N9
accine + MF59 treated mice (group 5) had minimal lesions. Micro-
copic lung lesions included severe bronchiolitis and alveolitis and
amage that included lymphocytic inﬁltration around peribron-
hiolar and perivascular areas in the PBS group (group 24). By
mmunohistochemical analysis, viral antigens could be detectednued).
in the lung, especially in the bronchiolar epithelium (Fig. 6C).
Based on these gross and microscopic lesions, the pathogenicity of
H7N9 viruses could be ranked in the following order, from greatest
to least: H7N9 + MF59 (group 5), H7N9 + alum (group 20), H7N9
(group 1), and ﬁnally MF59 (group 9), Yugangning (group 16),
and PBS group (group 24); no obvious differences were observed
between the ﬁnal three groups.
4. Discussion
Reverse transcription technology can aid the development of
seed strains especially for the highly pathogenic H5 or H7 strains
in which the major molecular features that confer this high vir-
ulence can be removed [20,21]. The H7N9/PR8 virus has many
characteristics that are desirable in an H7N9 vaccine candidate.
Unfortunately, because of the relatively poor immunogenicity of
split vaccines, at least two doses of vaccine must be provided [9]
along with an adjuvant [22]. MF59 seasonal inﬂuenza vaccines were
ﬁrst licensed for elderly individuals and previous large-scale anal-
ysis supported its good safety proﬁle [23]. Although vaccines must
undergo strict preclinical safety evaluation before licensing. How-
ever, cases of developing serious adverse events following inﬂuenza
vaccinations with adjuvant had been reported [24,25], among them
the implications of adjuvants in the development of autoimmune
diseases continues to receive considerable attention at recent years
[25], although such adverse reaction was rare and in most cases
related to myotoxic drugs use [26,27]. Some researchers even claim
inﬂuenza vaccine does not produce myopathy in patients taking
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Fig. 4. Antibody responses, including (A) HI antibodies, (B) MN antibodies, and (C) IgG titers, for groups of mice 1 week after virus inoculation. Each dot represents the
geometric mean titer obtained from groups of 6 mice. Mouse were intramuscular injected twice with various dosage of following immune formulations: Groups 1, 2, 3 and
4  (H7N9), Groups 5, 6, 7 and 8 (H7N9 + MF59, dosage of MF59 decreased synchronize with dosage of H7N9 in these four groups), Groups 9, 10, 11 and 12 (MF59), Groups 13,
14,  and 15 (H7N9 + MF59, dosage of MF59 maintained the highest dosage of 0.05 ml/mouse), Groups 16, 17, 18 and 19 (Yuganning); Groups 20, 21, 22 and 23 (H7N9 + alum);
Groups  24 was  PBS control group.
Fig. 5. (A) Weight loss after virus inoculation. The Y-axis shows weight loss that was  calculated as follows: ([weight at 1 week after virus inoculation − weight before virus
inoculation]/weight before virus inoculation) × 100. (B) Virus titers of lungs 1 week after H7N9 virus inoculation. Replications of H7N9-WT challenged viruses 1 week after
virus  inoculation in lungs of immunized BALB/c mice were determined using the TCID50 method in MDCK cells. Virus titers in lungs are expressed as means ± SE of the log10
TCID50 per g tissue. Mouse were intramuscular injected twice with various dosage of following immune formulations: Groups 1, 2, 3 and 4 (H7N9), Groups 5, 6, 7 and 8
( se fou
d  and 1
g
s
l
u
c
i
a
i
c
o
m
tH7N9  + MF59, dosage of MF59 decreased synchronize with dosage of H7N9 in the
osage  of MF59 maintained the highest dosage of 0.05 ml/mouse), Groups 16, 17, 18
roup.
tatins [28]. Unfortunately, cases of developing rhabdomyolysis fol-
owing inﬂuenza vaccinations are not accidental and the cause is
nclear, careful attention should be paid to adjuvant safety espe-
ially to concomitant medication inquiry when administrating the
nﬂuenza vaccine. It has been reported that MF59 can reduce the
ntigen requirements of H5N1 vaccines by at least six-fold and can
nduce a protective response after only a single dose [10,29]. By
ontrast, the addition of the classic immunoadjuvant alum to split
r subunit inﬂuenza vaccines has only been reported to induce
arginal improvements [30,31]. In this present study, we note
hat adjuvanting H7N9 antigen with MF59 or alum resulted inr groups), Groups 9, 10, 11 and 12 (MF59), Groups 13, 14, and 15 (H7N9 + MF59,
9 (Yuganning); Groups 20, 21, 22 and 23 (H7N9 + alum); Groups 24 was PBS control
comparatively higher levels of HI and MN antibodies and IgG titers,
and ultimately increased protection against H7N9 inﬂuenza virus.
Our ﬁndings suggest that MF59 has more advantages in improving
immune responses of split inﬂuenza vaccine compared with alum,
while neither MF59 nor alum could induce MN antibody production
after single dose immunization. In our present study, the HI, MN,
and IgG titers in serum after a ﬁrst immunization were obviously
low and were considered to be insufﬁcient to provide adequate
protection.
The induction of cellular immune responses is an attractive goal
for inﬂuenza vaccine research because such immunity targets the
H. Ou et al. / Vaccine 34 (2016) 2362–2370 2369
Fig. 6. Different degrees of injury in the lung 1 week after virus inoculation (original magniﬁcation, 200×). For groups 1 (H7N9), 5 (H7N9 + MF59), 9 (MF59), 16 (Yuganning),
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i0  (H7N9 + Alum), and 24 (PBS), H&E staining of lungs from mice in these groups 
ariable degrees of injury (minor, moderate, and severe) 1 week after virus inocula
ost conserved viral proteins [32] and tends to be more cross-
eactive against other virus strains [33,34]. The cellular immune
esponse to inﬂuenza virus was determined using a splenocyte pro-
iferation assay, along with measurements of Th1 and Th2 cytokines
n serum and supernatants of HA-stimulated cultured spleno-
ytes. The MF59-adjuvanted H7N9 split vaccine induced slightly
igher proliferative responses against homologous antigen com-
ared with the PBS- or H7N9 alone-treated groups, but showed a
esponse that was similar that of the alum + H7N9-treated group.
ytokines play a critical role in mediating immune responses, and
t is likely that many of the activities induced by adjuvants are
ediated by cytokines. Notably, more Th-2 cytokines, including
L-4 and IL-10, were detected in serum from mice immunized
ith H7N9 + MF59, especially after virus inoculation of from the
upernatants of splenocytes isolated from mice immunized with
7N9 + MF59 that were restimulated with HA antigen ex vivo.
h2-type responses have been typically associated with B cell
timulation and antibody production. By contrast, the release of
h1-type cytokines including, IFN- and of IL-2, have typically
een associated with cellular immunity, which is responsible for
he stimulation of CTLs [32]. We  veriﬁed that the adjuvants MF59
nd alum are poor inducers of Th1 responses and CTL activities,
hich might be related to the high concentrations of IFN- and
an be generally immunosuppressive. Indeed, most Th1 clones are
irectly cytotoxic for activated B cells [35]. Recent advances have
uggested a critical role for IL-17 in vaccine-induced protective
ellular responses and in generating effective long-lived vaccine-
nduced antiviral immunity [36]. Thus, we veriﬁed that MF59 can
obustly stimulate Th17 responses.
In summary, a monovalent inactivated split vaccine that we
repared from the H7N9/PR8 virus and mixed with MF59 was
mmunogenic and protected mice from subsequent Zhejiang virusk after virus inoculation. (a–c) Immunohistochemical staining of lungs exhibiting
challenge and we  believe this split H7N9 vaccine is able to protect
against other H7N9 virus without major HA antigenic drift. Both
MF59 and alum could enhance the priming of Ab levels, exert a Th2
bias, while MF59 exerted more robust responses. Further studies
that include the challenge of vaccinated mice at a later time point,
antibody isotype analysis, duration of immunity, and identiﬁcation
of protective epitopes and most importantly, human testing and
risk evaluations will be necessary.
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